在非糖尿病性病中使用糖共传输体-2 抑制剂:在实验模型中的证据
Giovanna Castoldi1, Raffaella Carletti2, Francesca Barzaghi1
1Dipartimento di Medicina e Chirurgia, Università degli Studi di Milano-Bicocca, 20900 Monza, Italy.
Pharmaceuticals (Basel, Switzerland)
|March 28, 2024
概括
糖共传输体2 (SGLT2) 抑制剂显示出除了糖尿病之外的脏保护的前景. 这些药物可以通过减少炎症和纤维化,在非糖尿病性病中提供好处.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖共运输体2 (SGLT2) 抑制剂已成为2型糖尿病的治疗方法.
- 临床试验显示,SGLT2抑制剂减缓了糖尿病病的进展.
研究的目的:
- 在非糖尿病病模型中审查SGLT2抑制剂的脏保护作用.
- 探索SGLT2抑制剂对脏保护作用的葡萄糖独立机制.
主要方法:
- 对非糖尿病病中SGLT2抑制剂的实验研究的综述.
- 对拟议的葡萄糖独立机制的详细分析.
主要成果:
- SGLT2 抑制剂在各种非糖尿病病模型中显示出保护作用.
- 有证据表明类作用包括减少炎症,纤维化,氧化应激和同情活动.
结论:
- SGLT2 抑制剂具有适用于非糖尿病脏疾病的脏保护性质.
- 葡萄糖独立的机制对SGLT2抑制剂对脏的益处有显著的贡献.
相关概念视频
Secondary Active Transport
119.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
119.7K
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Glucose Absorption Into the Small Intestine
31.6K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.6K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184


